{{knowledge objective
|Identifiant=OIC-078-17-B
|Item_parent=Addiction to cannabis, cocaine, amphetamines, opiates, synthetic drugs. (see item 322)
|Item_parent_short=Addiction to cannabis, cocaine, amphetamines, opiates, synthetic drugs. (see item 322)
|Rank=B
|Title=Know how to treat dependence.
|Description=Great principles
|Heading=Management
|Contributors=
|Order=17}}
'''Cannabis/Cocaine/Amphetamines/New synthetic products (cathinones, cannabinoids) :'''

.     No drug has been granted marketing authorisation in France for the treatment of drug dependence.

.     No drug treatment to prevent the resumption of misuse

.     No substitution treatment

.     Combining pharmacological treatments, cognitive and behavioural therapy and medical and psychosocial support

.     Using risk and harm reduction strategies

.     Management of psychiatric, non-psychiatric and addictive medical co-morbidities

'''Opiates/opioids:'''

.     Identical approach

.     Opioid substitution treatment

'''Risk and harm reduction (RDRD)'''

- In CAARUDs and CSAPAs

- Welcoming users, whatever their situation;

- Contact with people who don't want to or can't stop drinking

- Informing people about the risks associated with drug use and how to prevent them through a variety of media, personalised advice and group activities

- Distribution and promotion of materials to prevent human-to-human transmission of infectious agents and septic risks (syringes, condoms, crack kits, etc.)

- Safer consumption rooms exist in several French towns;

- Recovery of used consumer equipment

- Promoting access to rights and care, directing people to specialist services

- encouraging support through self-help groups